Lipocine Inc

NASDAQ:LPCNUnited States

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Contact Information

Headquarters

675 S Arapeen Dr Ste 202SALT LAKE CITY, UT, United States 84108-1295

Phone

801-994-7383

Fax

801-994-7388

Executives

Independent Chairman of the Board, Lead Independent Director

Spyros Papapetropoulos

President, Chief Executive Officer, Director

Mahesh Patel

Senior Vice President - Research and Development

Nachiappan Chidambaram

Principal Accounting Officer, Controller

Krista Fogarty

Director

John Higuchi